Vernalis announces positive results for Parkinson's Disease treatment study

AIM-listed pharmaceutical company Vernalis has published positive results for a Receptor Occupancy study of an antagonist with potential applications for Parkinson's disease and other Central Nervous System indications.

AIM-listed pharmaceutical company Vernalis has published positive results for a Receptor Occupancy study of an antagonist with potential applications for Parkinson's disease and other Central Nervous System indications.

The study examined the relationship between dose, plasma concentration and blockade of the so-called "A2A" receptor using positron emission tomography scanning and included a preliminary evaluation, using functional magnetic resonance imaging of the effects of V81444, the particular antangonist, on cognitive function.

The study demonstrated that full A2A blockade could be achieved with single doses that were within the range of doses previously shown to be well tolerated with no safety concerns.

As such, the study has provided confirmation of the appropriate dose to be used in the forthcoming clinical proof-of-concept trial.

Vernalis now plans to initiate, in the first half of next year, a Phase IIa proof-of-concept study to further evaluate the pharmacokinetics, safety and tolerability of V81444 in patients, together with an evaluation of efficacy in a target patient population.

Ian Garland, Chief Executive Officer of Vernalis, commented: "We are very pleased with these results and are already actively preparing for the continued development of this exciting programme over the next 12 months".

Vernalis's share price was up 0.55% to 23p at 09:27 on Wednesday morning.

MF

Recommended

Too embarrassed to ask: what is short selling?
Too embarrassed to ask

Too embarrassed to ask: what is short selling?

Short sellers are often accused of unfairly driving share prices down to make a quick buck. But short selling is a perfectly legitimate – if risky – t…
26 Jan 2021
Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020

Most Popular

The FTSE 100 is set for a makeover with an influx of new tech stocks
UK stockmarkets

The FTSE 100 is set for a makeover with an influx of new tech stocks

The FTSE 100 – the dullest index in the world – is about to reinvent itself as a host of new firms list on the market. The change is long overdue, say…
24 Jan 2021
Think Tesla is a bubble? This might be the best way to bet on it bursting
Oil

Think Tesla is a bubble? This might be the best way to bet on it bursting

The huge rise in Tesla’s share price means that, by market value, it’s now the sixth-largest company in the US and and the world’s biggest car-maker. …
25 Jan 2021
Why we won’t see a house-price crash in 2021
House prices

Why we won’t see a house-price crash in 2021

Lockdown sent house prices berserk as cooped up home-workers fled for bigger properties in the country. And while they won’t rise quite as much this y…
18 Jan 2021